Promising cancer therapy lutathera tested after liver surgery – study stopped early
NCT ID NCT05987176
First seen Jan 17, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This study looked at whether a radioactive drug called Lutathera, given after surgery to remove liver tumors from neuroendocrine cancer, could help keep the cancer from coming back. It compared Lutathera to standard monitoring (best supportive care) in people with low- or medium-grade tumors. The trial was stopped early after enrolling only one person, so no clear conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.